CSL Behring

Company snapshot

CSL Behring is a pharma organization headquartered in Marburg, DE. Primary therapeutic focus areas include Oral Mucositis, Complex Cardiovascular Surgery With Cardiopulmonary Bypass, Rheumatoid Arthritis, Antibody-mediated Rejection, Hemophilia A With Inhibitors. NovaPharmaNews links 7 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (4), phase 2 (2), phase 1 (1).

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 25 US patent(s) indexed to this assignee profile.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CSL Behring. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for CSL Behring.

1. Jun 8, 2026 Clinical update

   Clazakizumab — Phase 3

2. Jun 8, 2026 Clinical update

   human immunoglobulin G — Phase 3

3. Jun 5, 2026 Clinical update

   CSL689 — Phase 3

4. May 26, 2026 Clinical update

   BE1116 — Phase 3

5. May 26, 2026 Clinical update

   ALD518 — Phase 2

View all clinical trial activity →

• What is CSL Behring?

  CSL Behring is a pharma organization headquartered in Marburg, DE. Primary therapeutic focus areas include Oral Mucositis, Complex Cardiovascular Surgery With Cardiopulmonary Bypass, Rheumatoid Arthritis, Antibody-mediated Rejection, Hemophilia A With Inhibitors. NovaPharmaNews l

• Is CSL Behring publicly traded?

  CSL Behring appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does CSL Behring develop or market?

  We link 6 drug profile(s) where CSL Behring is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/csl-behring-gmbh#company-drugs.

• What are the latest developments for CSL Behring?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does CSL Behring focus on?

  CSL Behring focuses on Oral Mucositis, Complex Cardiovascular Surgery With Cardiopulmonary Bypass, Rheumatoid Arthritis based on our analysis of their pipeline programs and drug development activities.